Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
History
The U.S. Food and Drug Administration (FDA) approved tazemetostat in January 2020, The FDA granted the application for tazemetostat accelerated approval and orphan drug designation. Ipsen cited the advice from the data monitoring committee who observed adverse events of secondary hematologic malignancies in the SYMPHONY-1 study. Ipsen's partner in China, Hutchmed, also withdrew tazemetostat in mainland China, Hong Kong and Macau. ==References==